Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Base Year
Historical Year
Forecast Year
The osteoporosis market size in the 7 major markets was valued at USD 13.9 billion in 2023, driven by increasing innovations and research activities. The market size is anticipated to grow at a CAGR of 3.58% during the forecast period of 2024-2032 to achieve a value of USD 19.9 billion by 2032.
Osteoporosis can be characterized by low bone mass, deterioration of bone tissue, bone sterility, and constant risk of fracturing the bones. The most common cause of a broken bone among the elderly is osteoporosis. Bones that are most affected by the condition include the vertebrae in the spine, forearm, the wrist, and the hip. This condition typically exhibits no symptoms until it is diagnosed during the examination of a fractured bone. It makes it hard for the patients to carry out regular daily life activities as a little amount of pressure or stress may result in a broken bone.
The development of new, more effective osteoporosis medications, and advancements in bone density testing, is also driving the osteoporosis market growth. Government support and initiatives aimed at improving bone health and lowering the incidence of osteoporosis-related fractures are also fuelling the market growth.
Prevalence of Osteoporosis to Drive the Market Growth
The market is expected to witness significant growth driven by the increase in the incidence of osteoporosis. According to the International Osteoporosis Foundation, osteoporosis causes more than 8.9 million fractures annually, resulting in a fracture every three seconds around the world. The market growth can be further attributed to the growing investment in research and development activities conducted by biotechnology and pharmaceutical companies. The increasing public awareness of the condition is also playing a crucial role in the increasing number of diagnoses, contributing to the osteoporosis market share. Moreover, the market is expected to be driven by the rising technological advancements and drug development, likely to bolster the market growth during the forecast period.
Innovations Expected to Bolster Market Growth
The market is expected to witness significant growth driven by ground-breaking innovations and developments in the forecast period. For instance, in June 2023, the development of a robotic pill that safely delivers injectable osteoporosis drugs. The highly encouraging efficacy has offered hope to individuals suffering from chronic conditions, such as osteoporosis, as the only route of administration currently available is painful injections. This pioneering technology has the potential to revolutionize treatment options for patients, providing a painless alternative to injections.
Technical Advancements to Bolster the Demand
The market growth is expected to be driven by the new technologically advanced developments, exemplified by the development of OsteoBoost by Bone Health Technologies. It is a vibration belt designed to fight osteoporosis and osteopenia. OsteoBoost has been developed on 15 years of published research, including research from NASA. Bone Health Technologies has filed for Class 2 Prescription De Novo Approval with the FDA. Such developments attract investors which plays a crucial role in the market development and stability, likely to aid the osteoporosis market size in the forecast period.
Government Initiatives to Aid the Growth
Additionally, increasing initiatives and efforts by non-government organizations towards creating awareness and providing solutions are collectively contributing to osteoporosis market growth. For instance, in Feb 2023, the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) signed an agreement to develop a strategic roadmap on bone health and aging and advocate for a public health strategy to prevent fractures among older people. This partnership with WHO is expected to enhance the prevention and management of osteoporosis at local, regional, and national levels resulting in an enhanced quality of life for individuals living with this condition.
Increasing Research and Clinical Trials Leading New Opportunities
The increasing number of clinical trials to examine the efficacy of a drug is a major factor responsible for the growth of the osteoporosis market value. In May 2023, new research showed how women taking romosozumab, a new anti-osteoporosis drug available on the NHS, might be at risk of a heart attack. The University of Bristol-led study analysed the genetic data on about 34,000 people. Romosomuzab is an effective medicine prescribed to women with severe osteoporosis to reduce the risk of fracture. Discoveries like this are expected to spark discussion among healthcare professionals and researchers to perform more research and find the truth. Additionally, it sparks competition in the market as it brings opportunities for pharmaceutical companies to develop more suitable drugs with no side effects and high efficacy, boosting the market size.
Market Breakup by Type
Market Breakup by Therapy
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Distribution Channel
Market Breakup by Region
The United States is dominating the market and is expected to continue dominating the market during the forecast period driven by the presence of key players and the high prevalence of osteoporosis patients in the region. The presence of a robust and high-tech healthcare infrastructure, coupled with the availability of advanced drugs, is expected to drive the osteoporosis market growth.
In November 2023, Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the approval of a generic version of Forteo in the United States. Teva's generic equivalent of Forteo (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device. Teriparatide injection is indicated to treat osteoporosis among certain women and men. Such announcements indicate more affordable options becoming available for treating osteoporosis and accessible to people in need. More affordable options can potentially increase access to osteoporosis treatment, leading to growing demand for these medications.
In May 2023, Amgen announced that Prolia® (denosumab) injection has been found effective in reducing the risk of fractures in postmenopausal women compared to a common pill treatment called oral alendronate. The announcement was based on new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program. The treatment was also associated with greater reductions in fracture risk over time. Consequentially, doctors and patients are expected to prefer Prolia due to the promising long-term results. This announcement could also encourage further research and development of similar treatments, making more options available to help manage osteoporosis effectively.
The key features of the osteoporosis market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Type |
|
Breakup by Therapy |
|
Breakup by Route of Administration |
|
Breakup by End User |
|
Breakup by Distribution Channel |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 13.9 billion in 2023, driven by the increasing geriatric population.
The market is anticipated to grow at a CAGR of 3.58% during the forecast period of 2024-2032 and is likely to reach a market value of USD 19.9 billion by 2032.
The growing geriatric population, increasing prevalence of osteoporosis, innovations, technical advancements, government initiatives, clinical trials, and R&D activities are among the major factors driving the market growth.
The market growth is influenced by the approval of new treatment options, such as the approval of a generic version of Forteo in the United States.
The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan. EU-4 is divided into Germany, France, Italy, and Spain.
There are two types of primary osteoporosis and secondary osteoporosis.
The therapies can be divided into bisphosphonates, selective estrogen receptor modulators, parathyroid hormone therapy, and RANK ligand inhibitors.
The routes of administration include oral and injectables, among others.
The distribution channels in the market include hospitals, retail pharmacies, and online pharmacies, among others.
Key players involved in the market are DAIICHI SANKYO COMPANY, Amgen Inc., Merck & Co., Inc, AbbVie Inc, Bayer AG, Johnson & Johnson Services, Inc., Sanofi., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Pfizer Inc., Astrazeneca, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc., and F. Hoffmann-La Roche Ltd.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share